1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common...

1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy...

1. Patients in the hemodiafiltration group reported a significant reduction in all-cause mortality compared to those in the hemodialysis group....

1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or...

1. Tranexamic acid significantly reduced life-threatening postpartum bleeding. 2. There were no differences in the risk of thromboembolic events. Evidence...

1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade...

1. Isaclimab significantly improved disease activity at 150 mg and 600 mg doses. 2. Adverse events were comparable between cohorts...

1. Patients in the MGT group reported a significantly greater progression-free survival than those in the standard platinum-based chemotherapy group....

1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction...

1. Mean reduction in home systolic blood pressure at 12 weeks was greater with GMRx2 than with dual combination therapy....